The innovation era: Where biology meets technology
By Julie Warner2026-03-05T17:58:00
Welcome to the March 2026 issue of Regulatory Rapporteur which focuses on biologicals.
Biologicals are redefining regulation. From complex biologics, cell and gene therapies and live biotherapeutics to biosimilars, innovation is outpacing frameworks. The articles in our March issue show why early, transparent regulatory dialogue, especially amid evolving European Medicines Agency and US Food and Drug Administration positions, is now critical to translating scientific breakthroughs into global patient access.